Igor Salvadé1, Vincent Aubert2, Jean-Pierre Venetz2, Dela Golshayan2, Anne-Catherine Saouli2, Maurice Matter3, Samuel Rotman4, Giuseppe Pantaleo2, Manuel Pascual5. 1. Transplantation Center and Service of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: igor.salvade@chuv.ch. 2. Transplantation Center and Service of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland. 3. Service of Visceral Surgery, Lausanne University Hospital, 1011 Lausanne, Switzerland. 4. Institute of Pathology, Lausanne University Hospital, 1011 Lausanne, Switzerland. 5. Transplantation Center and Service of Immunology and Allergy, Lausanne University Hospital, 1011 Lausanne, Switzerland. Electronic address: manuel.pascual@chuv.ch.
Abstract
BACKGROUND: Pretransplant anti-HLA donor-specific antibodies (DSA) are recognized as a risk factor for acute antibody-mediated rejection (AMR) in kidney transplantation. The predictive value of C4d-fixing capability by DSA or of IgG DSA subclasses for acute AMR in the pretransplant setting has been recently studied. In addition DSA strength assessed by mean fluorescence intensity (MFI) may improve risk stratification. We aimed to analyze the relevance of preformed DSA and of DSA MFI values. METHODS: 280 consecutive patients with negative complement-dependent cytotoxicity crossmatches received a kidney transplant between 01/2008 and 03/2014. Sera were screened for the presence of DSA with a solid-phase assays on a Luminex flow analyzer, and the results were correlated with biopsy-proven acute AMR in the first year and survival. RESULTS: Pretransplant anti-HLA antibodies were present in 72 patients (25.7%) and 24 (8.6%) had DSA. There were 46 (16.4%) acute rejection episodes, 32 (11.4%) being cellular and 14 (5.0%) AMR. The incidence of acute AMR was higher in patients with pretransplant DSA (41.7%) than in those without (1.6%) (p<0.001). The median cumulative MFI (cMFI) of the group DSA+/AMR+ was 5680 vs 2208 in DSA+/AMR- (p=0.058). With univariate logistic regression a threshold value of 5280 cMFI was predictive for acute AMR. DSA cMFI's ability to predict AMR was also explored by ROC analysis. AUC was 0.728 and the best threshold was a cMFI of 4340. Importantly pretransplant DSA>5280 cMFI had a detrimental effect on 5-year graft survival. CONCLUSIONS: Preformed DSA cMFI values were clinically-relevant for the prediction of acute AMR and graft survival in kidney transplantation. A threshold of 4300-5300 cMFI was a significant outcome predictor.
BACKGROUND: Pretransplant anti-HLA donor-specific antibodies (DSA) are recognized as a risk factor for acute antibody-mediated rejection (AMR) in kidney transplantation. The predictive value of C4d-fixing capability by DSA or of IgG DSA subclasses for acute AMR in the pretransplant setting has been recently studied. In addition DSA strength assessed by mean fluorescence intensity (MFI) may improve risk stratification. We aimed to analyze the relevance of preformed DSA and of DSA MFI values. METHODS: 280 consecutive patients with negative complement-dependent cytotoxicity crossmatches received a kidney transplant between 01/2008 and 03/2014. Sera were screened for the presence of DSA with a solid-phase assays on a Luminex flow analyzer, and the results were correlated with biopsy-proven acute AMR in the first year and survival. RESULTS: Pretransplant anti-HLA antibodies were present in 72 patients (25.7%) and 24 (8.6%) had DSA. There were 46 (16.4%) acute rejection episodes, 32 (11.4%) being cellular and 14 (5.0%) AMR. The incidence of acute AMR was higher in patients with pretransplant DSA (41.7%) than in those without (1.6%) (p<0.001). The median cumulative MFI (cMFI) of the group DSA+/AMR+ was 5680 vs 2208 in DSA+/AMR- (p=0.058). With univariate logistic regression a threshold value of 5280 cMFI was predictive for acute AMR. DSA cMFI's ability to predict AMR was also explored by ROC analysis. AUC was 0.728 and the best threshold was a cMFI of 4340. Importantly pretransplant DSA>5280 cMFI had a detrimental effect on 5-year graft survival. CONCLUSIONS: Preformed DSA cMFI values were clinically-relevant for the prediction of acute AMR and graft survival in kidney transplantation. A threshold of 4300-5300 cMFI was a significant outcome predictor.
Authors: Alexander Kaltenborn; Almut Nolte; Ysabell Schwager; Simon A Littbarski; Nikos Emmanouilidis; Viktor Arelin; Jürgen Klempnauer; Harald Schrem Journal: Langenbecks Arch Surg Date: 2016-08-09 Impact factor: 3.445
Authors: E G Kamburova; B W Wisse; I Joosten; W A Allebes; A van der Meer; L B Hilbrands; M C Baas; E Spierings; C E Hack; F E van Reekum; A D van Zuilen; M C Verhaar; M L Bots; A C A D Drop; L Plaisier; M A J Seelen; J S F Sanders; B G Hepkema; A J A Lambeck; L B Bungener; C Roozendaal; M G J Tilanus; C E Voorter; L Wieten; E M van Duijnhoven; M Gelens; M H L Christiaans; F J van Ittersum; S A Nurmohamed; N M Lardy; W Swelsen; K A van der Pant; N C van der Weerd; I J M Ten Berge; F J Bemelman; A Hoitsma; P J M van der Boog; J W de Fijter; M G H Betjes; S Heidt; D L Roelen; F H Claas; H G Otten Journal: Am J Transplant Date: 2018-04-16 Impact factor: 8.086
Authors: Nicole Wittenbrink; Sabrina Herrmann; Arturo Blazquez-Navarro; Chris Bauer; Eric Lindberg; Kerstin Wolk; Robert Sabat; Petra Reinke; Birgit Sawitzki; Oliver Thomusch; Christian Hugo; Nina Babel; Harald Seitz; Michal Or-Guil Journal: BMC Immunol Date: 2019-04-27 Impact factor: 3.615
Authors: Ana Navas; Juan Molina; María-Luisa Agüera; Ipek Guler; Aurora Jurado; Alberto Rodríguez-Benot; Corona Alonso; Rafael Solana Journal: Front Immunol Date: 2019-08-02 Impact factor: 7.561
Authors: Mepur H Ravindranath; Narendranath M Ravindranath; Senthamil R Selvan; Edward J Filippone; Carly J Amato-Menker; Fatiha El Hilali Journal: Vaccines (Basel) Date: 2022-02-21